Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.
Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.
Merit Medical Systems, Inc. (NASDAQ: MMSI) will announce its financial results for Q2 2020 after the market closes on July 29, 2020. Following this, an investor conference call is scheduled for the same day at 5:00 p.m. Eastern. Interested parties can participate by calling (844) 578-9672 domestically or (508) 637-5656 internationally, and a live webcast will be available on their website. Founded in 1987, Merit specializes in disposable medical devices used in various medical fields, employing around 6,000 people globally.
Merit Medical Systems (NASDAQ: MMSI) has reached an agreement with the Department of Justice to resolve its marketing practices investigation, expecting to pay $18 million while denying the allegations. CEO Fred P. Lampropoulos stated that this resolution is beneficial for the business, allowing the company to refocus on customer service. The final settlement details will be released once the documents are finalized. Merit, established in 1987, specializes in developing and distributing disposable medical devices across various medical fields, employing around 6,000 individuals globally.
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced the nomination of three independent directors—Lonny Carpenter, David Floyd, and James Hogan—for election at the upcoming 2020 Annual Meeting on June 22. The new appointments aim to enhance shareholder value and add industry experience. The current board members Nolan Karras, David Liu, and Lynne Ward will not seek re-election, while Franklin Miller will resign post-meeting. Additionally, an Operating Committee will be formed to establish operating margin targets. Starboard Value LP, which holds 8.7% of shares, supports these changes.
Merit Medical Systems (NASDAQ: MMSI) announced on May 26, 2020, that it has received the CE mark for its WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI). This device aims to treat stenosis or occlusion in hemodialysis patients and is set to be introduced in Europe as procedures resume post-COVID-19. Merit has worked on this product for nearly eight years and recently completed the WRAPSODY FIRST study with 46 patients. The company also submitted an IDE application to the FDA for its upcoming WAVE Pivotal Study.